{
    "info": {
        "nct_id": "NCT03774472",
        "official_title": "Phase I/II Safety and Efficacy Study of Autophagy Inhibition With Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib Plus Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer",
        "inclusion_criteria": "* Signed written informed consent\n* Diagnosis of estrogen positive breast cancer, estrogen receptor-positive and HER2-negative by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Postmenopausal defined by: a. Age >= 55 years and 1 year or more of amenorrhea b. Age < 55 years and 1 year or more of amenorrhea with luteinizing hormone (LH) and/or follicle stimulating hormone (FSH) levels in the postmenopausal range c. Age < 55 with prior hysterectomy but intact ovaries with LH and/or FSH levels in the postmenopausal range d. Chemotherapy or medically induced ovarian suppression with 1 year or more of amenorrhea and with LH and/or FSH levels in the postmenopausal range e. Status after bilateral oophorectomy (>= 28 days prior to first study treatment)\n* Absolute neutrophil count (ANC) >= 1500 cells/ul\n* Platelet count >= 100,000/ul\n* Serum creatinine concentration < 1.5 x upper limit of normal (ULN)\n* Bilirubin level < 1.5 x ULN\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN\n* Alkaline phosphatase =< 2.5 ULN\n* Metastatic cohorts (Phase I): Diagnosis of stage IV estrogen positive breast cancer, estrogen receptor-positive and HER2-negative by ASCO/CAP criteria\n* Metastatic cohorts (Phase I): Must be a candidate for treatment with CDK4/6 inhibitor and hormonal therapy with an aromatase inhibitor as standard of care\n* Metastatic cohorts (Phase I): No prior exposure to CDK 4/6 inhibitors\n* Neoadjuvant cohorts (Phase II): Diagnosis of stage I-III estrogen positive breast cancer, estrogen receptor-positive and HER2-negative by ASCO/CAP criteria. If stage I, clinical tumor size must be >= 1.5 cm\n* Neoadjuvant cohorts (Phase II): Baseline tumor Ki67 > 5%\n* Neoadjuvant cohorts (Phase II): Surgical candidate and appropriate for pre-operative endocrine therapy\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior exposure to CDK 4/6 inhibitor therapy\n* History of retinal disease or active visual disturbances (normal baseline study-specified retinal exam required)\n* Acute illness, including infections requiring medical therapy, known bleeding diathesis or need for anticoagulation\n* Treatment with any of the following medications within 4 weeks before the baseline diagnostic biopsy is taken: a. Oral estrogens, including hormone replacement therapy (but prior depot estrogen use not allowed). b. Investigational agents (or 5 half-lives, whichever is longer)\n* Required concomitant use of any drug that is a strong CYP3A inhibitor or inducer\n* Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol\n* Life expectancy of less than 6 months\n* Pregnancy, lactation or planning to be pregnant.\n* Neo-adjuvant cohorts (Phase II): Prior therapy for breast cancer (medical, surgical or radiation therapy)\n* Neo-adjuvant cohorts (Phase II): Clinical T4 disease\n* Neo-adjuvant cohorts (Phase II): Inoperable or metastatic breast cancer based on standard evaluation",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Bilirubin level < 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin level < 1.5 x ULN",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Neoadjuvant cohorts (Phase II): Diagnosis of stage I-III estrogen positive breast cancer, estrogen receptor-positive and HER2-negative by ASCO/CAP criteria. If stage I, clinical tumor size must be >= 1.5 cm",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of stage I-III estrogen positive breast cancer",
                    "criterion": "breast cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "estrogen positive breast cancer, estrogen receptor-positive",
                    "criterion": "estrogen receptor status",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2-negative by ASCO/CAP criteria",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "negativity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "ASCO/CAP criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "If stage I, clinical tumor size must be >= 1.5 cm",
                    "criterion": "clinical tumor size (for stage I)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1500 cells/ul",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1500 cells/ul",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "cells/ul"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Neoadjuvant cohorts (Phase II): Baseline tumor Ki67 > 5%",
            "criterions": [
                {
                    "exact_snippets": "Baseline tumor Ki67 > 5%",
                    "criterion": "tumor Ki67",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alkaline phosphatase =< 2.5 ULN",
            "criterions": [
                {
                    "exact_snippets": "Alkaline phosphatase =< 2.5 ULN",
                    "criterion": "alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 100,000/ul",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000/ul",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/ul"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of estrogen positive breast cancer, estrogen receptor-positive and HER2-negative by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of estrogen positive breast cancer",
                    "criterion": "estrogen positive breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "estrogen receptor-positive",
                    "criterion": "estrogen receptor status",
                    "requirements": [
                        {
                            "requirement_type": "receptor status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2-negative",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "receptor status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria",
                    "criterion": "ASCO/CAP criteria",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "ASCO/CAP"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Metastatic cohorts (Phase I): Diagnosis of stage IV estrogen positive breast cancer, estrogen receptor-positive and HER2-negative by ASCO/CAP criteria",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of stage IV estrogen positive breast cancer",
                    "criterion": "breast cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    ]
                },
                {
                    "exact_snippets": "estrogen positive breast cancer, estrogen receptor-positive",
                    "criterion": "estrogen receptor status",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2-negative by ASCO/CAP criteria",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "negativity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "ASCO/CAP criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Metastatic cohorts (Phase I): Must be a candidate for treatment with CDK4/6 inhibitor and hormonal therapy with an aromatase inhibitor as standard of care",
            "criterions": [
                {
                    "exact_snippets": "Must be a candidate for treatment with CDK4/6 inhibitor",
                    "criterion": "candidate for CDK4/6 inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Must be a candidate for treatment with ... hormonal therapy with an aromatase inhibitor",
                    "criterion": "candidate for hormonal therapy with an aromatase inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as standard of care",
                    "criterion": "standard of care",
                    "requirements": [
                        {
                            "requirement_type": "treatment context",
                            "expected_value": "standard of care"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine concentration < 1.5 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine concentration < 1.5 x upper limit of normal (ULN)",
                    "criterion": "serum creatinine concentration",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... < 3 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) < 3 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Neoadjuvant cohorts (Phase II): Surgical candidate and appropriate for pre-operative endocrine therapy",
            "criterions": [
                {
                    "exact_snippets": "Surgical candidate",
                    "criterion": "surgical candidacy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "appropriate for pre-operative endocrine therapy",
                    "criterion": "appropriateness for pre-operative endocrine therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Signed written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "written",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Postmenopausal defined by: a. Age >= 55 years and 1 year or more of amenorrhea b. Age < 55 years and 1 year or more of amenorrhea with luteinizing hormone (LH) and/or follicle stimulating hormone (FSH) levels in the postmenopausal range c. Age < 55 with prior hysterectomy but intact ovaries with LH and/or FSH levels in the postmenopausal range d. Chemotherapy or medically induced ovarian suppression with 1 year or more of amenorrhea and with LH and/or FSH levels in the postmenopausal range e. Status after bilateral oophorectomy (>= 28 days prior to first study treatment)",
            "criterions": [
                {
                    "exact_snippets": "Age >= 55 years and 1 year or more of amenorrhea",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 55,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Age >= 55 years and 1 year or more of amenorrhea",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Age < 55 years and 1 year or more of amenorrhea with luteinizing hormone (LH) and/or follicle stimulating hormone (FSH) levels in the postmenopausal range",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 55,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Age < 55 years and 1 year or more of amenorrhea with luteinizing hormone (LH) and/or follicle stimulating hormone (FSH) levels in the postmenopausal range",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "luteinizing hormone (LH) and/or follicle stimulating hormone (FSH) levels in the postmenopausal range",
                    "criterion": "LH and/or FSH levels",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "postmenopausal range"
                        }
                    ]
                },
                {
                    "exact_snippets": "Age < 55 with prior hysterectomy but intact ovaries with LH and/or FSH levels in the postmenopausal range",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 55,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior hysterectomy but intact ovaries",
                    "criterion": "hysterectomy status",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": "prior hysterectomy"
                        }
                    ]
                },
                {
                    "exact_snippets": "prior hysterectomy but intact ovaries",
                    "criterion": "ovarian status",
                    "requirements": [
                        {
                            "requirement_type": "integrity",
                            "expected_value": "intact"
                        }
                    ]
                },
                {
                    "exact_snippets": "LH and/or FSH levels in the postmenopausal range",
                    "criterion": "LH and/or FSH levels",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "postmenopausal range"
                        }
                    ]
                },
                {
                    "exact_snippets": "Chemotherapy or medically induced ovarian suppression with 1 year or more of amenorrhea and with LH and/or FSH levels in the postmenopausal range",
                    "criterion": "ovarian suppression",
                    "requirements": [
                        {
                            "requirement_type": "induction",
                            "expected_value": [
                                "chemotherapy induced",
                                "medically induced"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "1 year or more of amenorrhea",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "LH and/or FSH levels in the postmenopausal range",
                    "criterion": "LH and/or FSH levels",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "postmenopausal range"
                        }
                    ]
                },
                {
                    "exact_snippets": "Status after bilateral oophorectomy (>= 28 days prior to first study treatment)",
                    "criterion": "bilateral oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Metastatic cohorts (Phase I): No prior exposure to CDK 4/6 inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Metastatic cohorts (Phase I)",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "No prior exposure to CDK 4/6 inhibitors",
                    "criterion": "prior exposure to CDK 4/6 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of exposure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* History of retinal disease or active visual disturbances (normal baseline study-specified retinal exam required)",
            "criterions": [
                {
                    "exact_snippets": "History of retinal disease",
                    "criterion": "retinal disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active visual disturbances",
                    "criterion": "visual disturbances",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "normal baseline study-specified retinal exam required",
                    "criterion": "retinal exam",
                    "requirements": [
                        {
                            "requirement_type": "baseline normality",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any of the following medications within 4 weeks before the baseline diagnostic biopsy is taken: a. Oral estrogens, including hormone replacement therapy (but prior depot estrogen use not allowed). b. Investigational agents (or 5 half-lives, whichever is longer)",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any of the following medications within 4 weeks before the baseline diagnostic biopsy is taken: a. Oral estrogens, including hormone replacement therapy (but prior depot estrogen use not allowed)",
                    "criterion": "oral estrogen treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with any of the following medications within 4 weeks before the baseline diagnostic biopsy is taken: ... b. Investigational agents (or 5 half-lives, whichever is longer)",
                    "criterion": "investigational agent treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": "within 4 weeks or 5 half-lives, whichever is longer"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol",
            "criterions": [
                {
                    "exact_snippets": "Psychological ... conditions that do not permit compliance with the study protocol",
                    "criterion": "psychological conditions",
                    "requirements": [
                        {
                            "requirement_type": "permit compliance with study protocol",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "familial ... conditions that do not permit compliance with the study protocol",
                    "criterion": "familial conditions",
                    "requirements": [
                        {
                            "requirement_type": "permit compliance with study protocol",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sociological ... conditions that do not permit compliance with the study protocol",
                    "criterion": "sociological conditions",
                    "requirements": [
                        {
                            "requirement_type": "permit compliance with study protocol",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "geographical conditions that do not permit compliance with the study protocol",
                    "criterion": "geographical conditions",
                    "requirements": [
                        {
                            "requirement_type": "permit compliance with study protocol",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute illness, including infections requiring medical therapy, known bleeding diathesis or need for anticoagulation",
            "criterions": [
                {
                    "exact_snippets": "Acute illness",
                    "criterion": "acute illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "infections requiring medical therapy",
                    "criterion": "infection requiring medical therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "known bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "need for anticoagulation",
                    "criterion": "need for anticoagulation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior exposure to CDK 4/6 inhibitor therapy",
            "criterions": [
                {
                    "exact_snippets": "Prior exposure to CDK 4/6 inhibitor therapy",
                    "criterion": "CDK 4/6 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Required concomitant use of any drug that is a strong CYP3A inhibitor or inducer",
            "criterions": [
                {
                    "exact_snippets": "Required concomitant use of any drug that is a strong CYP3A inhibitor or inducer",
                    "criterion": "concomitant use of strong CYP3A inhibitor or inducer",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug property",
                            "expected_value": [
                                "strong CYP3A inhibitor",
                                "strong CYP3A inducer"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Neo-adjuvant cohorts (Phase II): Prior therapy for breast cancer (medical, surgical or radiation therapy)",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy for breast cancer (medical, surgical or radiation therapy)",
                    "criterion": "prior therapy for breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "medical",
                                "surgical",
                                "radiation therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Neo-adjuvant cohorts (Phase II): Clinical T4 disease",
            "criterions": [
                {
                    "exact_snippets": "Clinical T4 disease",
                    "criterion": "clinical T4 disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy, lactation or planning to be pregnant.",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactation",
                    "criterion": "lactation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "planning to be pregnant",
                    "criterion": "plans to become pregnant",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Neo-adjuvant cohorts (Phase II): Inoperable or metastatic breast cancer based on standard evaluation",
            "criterions": [
                {
                    "exact_snippets": "Inoperable ... breast cancer",
                    "criterion": "breast cancer operability",
                    "requirements": [
                        {
                            "requirement_type": "operability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic breast cancer",
                    "criterion": "breast cancer metastasis",
                    "requirements": [
                        {
                            "requirement_type": "metastatic status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of less than 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of less than 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}